Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.